Prescribing Information LYNPARZA (olaparib) United Kingdom

This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk

Dosing

LYNPARZA can be taken twice daily, either as a monotherapy or as part of a treatment plan that includes abiraterone and prednisone/prednisolone¹

Please see homepage or respective LYNPARZA pages for full indication

Before initiation of LYNPARZA treatment:¹

- For LYNPARZA monotherapy treatment in BRCA1/2-mutated mCRPC, patients must have confirmation of a deleterious or suspected deleterious BRCA1/2 mutation before LYNPARZA treatment is initiated

- No genomic testing is required prior to using LYNPARZA in combination with abiraterone and prednisone/prednisolone for the treatment of patients with mCRPC

For further information on patient monitoring requirements before and during LYNPARZA treatment,see below or consult the SmPC.

LYNPARZA monotherapy and combined therapy dosing regimen

Treatment with LYNPARZA should be continued until progression of the underlying disease or unacceptable toxicity when used as monotherapy or when used in combination with abiraterone and prednisone/prednisolone.¹

In the case of LYNPARZA monotherapy, LYNPARZA dosing remains the same but without the addition of abiraterone or prednisone/prednisolone.¹

In patients who have not been surgically castrated, patients receiving LYNPARZA monotherapy should also receive a luteinising hormone-releasing hormone (LHRH) analogue, and those receiving LYNPARZA plus abiraterone should receive gonadotropin-releasing hormone (GnRH) analogue concurrently.¹

Important things to remember when prescribing LYNPARZA^1–4

If a patient misses a dose of LYNPARZA, the next dose should be taken at its scheduled time.

Patients should not take more than four LYNPARZA tablets per day. If a patient takes more than four tablets, they should contact you, their HCP, and go to their local hospital emergency department.

All tablets should be swallowed whole; they should not be chewed, crushed, dissolved or divided as this may affect the drug’s absorption into the body.

Grapefruit and grapefruit juice should be avoided whilst a patient is receiving LYNPARZA. For the full list of contraindications, please see the Summary of Product Characteristics.

If dose reductions of LYNPARZA are required, tablets are also available in a 100 mg formulation.

If a patient experiences vomiting after taking their dose of LYNPARZA, they should not take a second dose unless the tablets are intact and both can be seen. The next dose should be taken at its scheduled time.

Patients should be instructed to keep a note of any side effects they experience, so they can easily share this information with you at their next appointment.

Use this guide to assist patients with mCRPC who are receiving LYNPARZA in understanding their therapy

SEE THE LYNPARZA PATIENT GUIDE

Dose adjustments to manage side effects

When in monotherapy or combination therapy, LYNPARZA treatment may be interrupted to manage adverse reactions, such as nausea, vomiting, diarrhoea and anaemia.¹

Dose interruptions

Diagram detailing dose adjustments to manage side effects for Lynparza

The recommended dose reduction of LYNPARZA is 250 mg twice a day in both monotherapy and combination therapy. If a further dose reduction is required, the second recommended reduction is to 200 mg twice a day.¹

Dose reductions

Diagram deatiling dosing reduction for Lynparza

The most common side effects with LYNPARZA can be generally managed with supportive treatment, dose interruptions and dose reductions, limiting the need for patients to discontinue.^5,6

Co-administration of LYNPARZA with strong or moderate CYP3A inhibitors is not recommended. If a strong or moderate CYP3A inhibitor must be co-administered, the dose of LYNPARZA should be reduced.¹

LYNPARZA co-administration with strong or moderate CYP3A inducers is not recommended. In the event that a patient already receiving LYNPARZA requires treatment with a strong or moderate CYP3A inducer, the prescriber should be aware that the efficacy of LYNPARZA may be substantially reduced.¹

It is recommended that the following biochemical markers are monitored for patients receiving LYNPARZA^1,3,7

Diagram detailing suggested biochemical markers to be monitored for patients receiving LYNPARZA

These management strategies were derived from clinical studies or established medical protocol. This information is not meant to replace the clinical judgment of the attending physician. Adverse reactions experienced by patients should be reported to AstraZeneca patient safety.

See details below on reporting adverse events

Learn more about the potential adverse events associated with LYNPARZA

VIEW HERE

Want to learn more about LYNPARZA?

AE=adverse event; CBC=complete blood count; CrCl=creatinine clearance; CTCAE=Common Terminology Criteria for Adverse Events; GnRH=gonadtropin-releasing hormone; HCP=healthcare professional; LHRH=luteinising hormone-releasing hormone; mCRPC=metastatic castration-resistant prostate cancer; VTE=venous thromboembolism.

LYNPARZA (olaparib). Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9204/smpc Accessed January 2026.
Clarke N, et al. NEJM Evid. 2022. doi:https://doi.org/10.1056/EVIDoa2200043.
LYNPARZA (olaparib tablets) Patient Information Leaflet. https://www.medicines.org.uk/emc/product/9204/pil Accessed January 2026.
Friedlander M, et al. Am Soc Clin Oncol Educ Book 2023;43:e390876.
Thiery-Vuillemin A, et al. Presented at ASCO Annual Meeting 2022; 3–7 June; Chicago, US; Abstract 5019.
Roubaud G, et al. Presented at ESMO Virtual Congress 2020; 19–21 September; Poster 624P.
PROpel Protocol v1.0.

GB-70879 | DOP: February 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Cookie Policy

Dosing

LYNPARZA can be taken twice daily, either as a monotherapy or as part of a treatment plan that includes abiraterone and prednisone/prednisolone1

Please see homepage or respective LYNPARZA pages for full indication

Before initiation of LYNPARZA treatment:1

- For LYNPARZA monotherapy treatment in BRCA1/2-mutated mCRPC, patients must have confirmation of a deleterious or suspected deleterious BRCA1/2 mutation before LYNPARZA treatment is initiated

- No genomic testing is required prior to using LYNPARZA in combination with abiraterone and prednisone/prednisolone for the treatment of patients with mCRPC

LYNPARZA monotherapy and combined therapy dosing regimen

Treatment with LYNPARZA should be continued until progression of the underlying disease or unacceptable toxicity when used as monotherapy or when used in combination with abiraterone and prednisone/prednisolone.1

In the case of LYNPARZA monotherapy, LYNPARZA dosing remains the same but without the addition of abiraterone or prednisone/prednisolone.1

In patients who have not been surgically castrated, patients receiving LYNPARZA monotherapy should also receive a luteinising hormone-releasing hormone (LHRH) analogue, and those receiving LYNPARZA plus abiraterone should receive gonadotropin-releasing hormone (GnRH) analogue concurrently.1

Important things to remember when prescribing LYNPARZA1–4

Use this guide to assist patients with mCRPC who are receiving LYNPARZA in understanding their therapy

Dose adjustments to manage side effects

When in monotherapy or combination therapy, LYNPARZA treatment may be interrupted to manage adverse reactions, such as nausea, vomiting, diarrhoea and anaemia.1

Dose interruptions

Dose reductions

LYNPARZA co-administration with strong or moderate CYP3A inducers is not recommended. In the event that a patient already receiving LYNPARZA requires treatment with a strong or moderate CYP3A inducer, the prescriber should be aware that the efficacy of LYNPARZA may be substantially reduced.1

It is recommended that the following biochemical markers are monitored for patients receiving LYNPARZA1,3,7

Learn more about the potential adverse events associated with LYNPARZA

Want to learn more about LYNPARZA?

Abbreviations and References

These Lynparza website pages were funded and produced by AstraZeneca UK and MSD UK.

Enhance your knowledge, stay informed

Be the first to know. Hear about events, products and ways to support your patients.

Thank you. We will be in touch